#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn {border: 0px solid #fff;border-radius: 0px;color: #fff;}#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn a {color: #fff!important;}#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn:hover {background-color: #000!important;border-color: #fff;color: #fff;}#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn:hover a {color: #fff!important;}
034E94A4AD674BAB87E63249BBB0F" data-expr="attr.options.title" data-index="-1" data-ckey="jmtitle" style="position: relative;">

Snibe Diagnostics: Advancing Immunodiagnostics with Fully Automated Chemiluminescence Systems

034E94A4AD674BAB87E63249BBB0F" data-expr="attr.options.subtitle" data-index="-1" data-ckey="jtext" style="position: relative;" spellcheck="false">

Snibe Diagnostics, based in Shenzhen, is a fast-growing innovator in the field of in-vitro diagnostics (IVD), specializing in chemiluminescence immunoassay (CLIA) platforms and high-performance diagnostic reagents. The company has established itself as a leader in China’s diagnostic equipment sector by combining automation, sensitivity, and reagent development into a unified diagnostic ecosystem.

  • 01

    034E94A4AD674BAB87E63249BBB0F" data-expr="item.title" data-index="0" data-ckey="jmctitle" data-key="items">

    Product Line

    034E94A4AD674BAB87E63249BBB0F" data-expr="item.content" data-index="0" data-ckey="jfctext" data-key="items" style="position: relative;" spellcheck="false">

    Snibe’s flagship product line features fully automated immunoassay analyzers that support a broad spectrum of diagnostic targets, including infectious diseases, tumor markers, hormones, and cardiovascular biomarkers. With fast throughput, high precision, and compact footprints, these platforms are widely adopted by hospitals, clinics, and third-party labs throughout Asia and emerging markets.

  • 02

    034E94A4AD674BAB87E63249BBB0F" data-expr="item.title" data-index="1" data-ckey="jmctitle" data-key="items">

    Innovative Development

    034E94A4AD674BAB87E63249BBB0F" data-expr="item.content" data-index="1" data-ckey="jfctext" data-key="items" style="position: relative;" spellcheck="false">

    The company’s in-house reagent development focuses on improving clinical sensitivity and expanding the scope of detectable biomarkers. With over 200 reagent products already approved for market, Snibe Diagnostics continues to invest in next-generation chemistries, multi-biomarker panels, and long-term stability solutions. Their manufacturing system adheres to international quality and traceability standards for medical diagnostics.

  • 03

    034E94A4AD674BAB87E63249BBB0F" data-expr="item.title" data-index="2" data-ckey="jmctitle" data-key="items">

    International Collaboration

    034E94A4AD674BAB87E63249BBB0F" data-expr="item.content" data-index="2" data-ckey="jfctext" data-key="items" style="position: relative;" spellcheck="false">

    To enhance its scientific depth, Snibe Diagnostics partners with top-tier universities such as the University of Oxford and the University of Toronto. These collaborations explore the development of novel biomarkers, precision immunoassay formats, and AI-assisted diagnostic modeling. Academic joint ventures also contribute to early-phase clinical validation and international regulatory research.

     

    By integrating high-throughput testing with biomarker discovery, Snibe Diagnostics aims to improve diagnostic efficiency and disease detection at earlier stages. Through strategic partnerships and continued innovation, the company is building the next generation of immunodiagnostic systems that combine accuracy, speed, and clinical relevance on a global scale.